Group 1 - The core viewpoint of the news is that Weigao Blood Purification has shown a slight increase in stock price and trading volume, with notable financing activities on December 1 [1] - On December 1, Weigao Blood Purification's stock price increased by 2.00%, with a trading volume of 117 million yuan. The financing buy-in amount was 12.26 million yuan, while the financing repayment was 12.74 million yuan, resulting in a net financing buy of -0.47 million yuan [1] - As of December 1, the total balance of margin trading for Weigao Blood Purification was 153 million yuan, accounting for 9.42% of its circulating market value [1] Group 2 - As of September 30, the number of shareholders for Weigao Blood Purification was 24,800, a decrease of 20.95% compared to the previous period. The average circulating shares per person increased by 26.51% to 1,535 shares [2] - For the period from January to September 2025, Weigao Blood Purification achieved an operating income of 2.736 billion yuan, representing a year-on-year growth of 3.45%. The net profit attributable to the parent company was 341 million yuan, with a year-on-year increase of 7.92% [2] - The company has distributed a total of 65.82 million yuan in dividends since its A-share listing [3]
威高血净12月1日获融资买入1226.45万元，融资余额1.53亿元